MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Aegerion Pharmaceuticals Company Profile (NASDAQ:AEGR)

Consensus Ratings for Aegerion Pharmaceuticals (NASDAQ:AEGR) (?)
Ratings Breakdown: 1 Sell Rating(s), 3 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.29)
Consensus Price Target: $14.83 (420.47% upside)

Analysts' Ratings History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Show:
DateFirmActionRatingPrice TargetActions
4/17/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Leerink SwannReiterated RatingOutperform$31.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/12/2016Bank of AmericaDowngradeNeutral -> Underperform$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/21/2015GuggenheimUpgradeSell -> Buy$7.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2015JPMorgan Chase & Co.Reiterated RatingNeutral$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015Jefferies GroupLower Price TargetBuy$26.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2015Needham & Company LLCReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/31/2014Deutsche BankDowngradeBuy -> Hold$58.00 -> $26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/27/2014Goldman SachsInitiated CoverageSell$27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2014Citigroup Inc.DowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2014FBR & Co.Lower Price TargetOutperform$111.00 -> $107.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/1/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha